New therapy combination yields high remission rates in early-stage Hodgkin lymphoma
Patients with early-stage Hodgkin lymphoma had impressive response rates when treated with a novel combination of therapies—brentuximab vedotin and nivolumab combined with chemotherapy drugs doxorubicin and dacarbazine—according ...
Jan 25, 2026
0
2









